Visual analogue scales (VAS) as exploratory evaluation of eight dimensions in prostate cancer (PCa) patients aged 60 years and older initiating a gonadotropin-releasing hormone agonist (GnRHa) therapy: Secondary analysis of PRISME study.

Christophe Hennequin,Pierre Mongiat-Artus,Morgan Rouprêt,Nathalie Pello Leprince Ringuet,Anne-Sophie Grandoulier,François Rozet

Visual analogue scales (VAS) as exploratory evaluation of eight dimensions in prostate cancer (PCa) patients aged 60 years and older initiating a gonadotropin-releasing hormone agonist (GnRHa) therapy: Secondary analysis of PRISME study.

2021

Christophe Hennequin
Pierre Mongiat-Artus
Morgan Rouprêt
Nathalie Pello Leprince Ringuet
Anne-Sophie Grandoulier
François Rozet

221Background: Age, PCa and GnRHa treatment may modify patients health-related quality of life (HRQOL) and clinical parameters routinely evaluated: health status, urinary function, sexual function,...

Keywords:

Prostate cancer
Quality of life
Oncology
Sexual function
Medicine
Internal medicine
secondary analysis
Urinary function
Gonadotropin-releasing hormone agonist

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations